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Abstract
Background: Telomere length is a marker of cumulative damage to the cell, and has been associated with 
cardiovascular disease, hypertension, and diabetes.
Findings: The association of telomere length with pre-eclampsia and gestational diabetes mellitus (GDM) was 
examined in a nested case-control study. Circulating leukocyte telomere length was measured by Quantitative-PCR. 
Mean and median telomere length among cases and controls was compared, and logistic regression was used to 
model the outcomes as a function of tertile telomere length, with control for effects of potential confounders. Mean 
telomere length in pre-eclampsia cases was 0.77 (SD 0.14), in GDM cases was 0.73 (SD 0.10), and in controls was 0.74 
(SD 0.14). The adjusted odds ratio comparing the highest tertile to the lowest for pre-eclampsia was 0.92 (0.15-5.46), 
and for gestational diabetes was 0.65 (0.13-3.34).
Conclusions: Further study is necessary to determine if telomere length is associated with these pregnancy 
complications.
Background
Telomeres are terminal regions of chromosomes that
comprise multiple tandem repeats of a base sequence[1]
Telomere length is a marker of the cumulative damage
the cell has been exposed to [2], and has been associated
with cardiovascular disease[3], general cardiovascular
damage [4], and atherosclerosis [5]. Hypertensive
patients have been reported to have shorter telomeres [6-
9], especially when they had high renin to aldosterone
ratios[10]. Similarly, blood pressure has been associated
with shorter telomeres and low telomerase activity [11-
13] Diabetes patients have been shown to have shorter
telomeres in several studies, [11,14-17] and increased
telomere attrition [18] and shorter telomere length [6,19]
have been associated with insulin resistance. Higher glu-
cose and insulin were associated with shorter telomeres
[11,20] and low telomerase activity [12], while good gly-
cemic control was associated with more favorable telom-
ere dynamics[17,20]
Telomere length and dynamics vary substantially
between individuals [21] and are influenced by a number
of factors, including genetics and family relationship
[13,22,23], multivitamin use [23], race [21], smoking
[12,21,24], and body mass index [6,18,24].
Pre-eclampsia is associated with increased risk of car-
diovascular disease [25] and gestational diabetes is asso-
ciated with increased risk of later diabetes[26], suggesting
that risk factors and etiologies of cardiovascular disease
and diabetes and these outcomes is likely to be similar.
Thus, a reasonable hypothesis is that telomere length will
also differ in patients with these outcomes. In addition,
telomere length has been associated with oxidative stress,
[16,27] and markers of oxidative stress are raised in pre-
eclampsia[28] A recent article found lower telomere
length in the placentas of women with pre-eclampsia and
intrauterine growth retardation[29] We are unaware of
other previous studies of telomere length in pre-eclamp-
sia and gestational diabetes. For studies related to repro-
ductive outcomes, no difference in telomere lengths was
found in young adults whose mothers had pre-gestational
type 1 diabetes[30], while another study of newborns did
not find statistically significant differences in telomere
lengths between newborns whose mothers had pre-
eclampsia, hypertension, or diabetes[31]. However, these
studies dealt with the child rather than the mothers.
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Recurrent miscarriage has also been associated with
shorter telomere length [32], but no difference in telom-
ere length by small-for-gestational-age was seen[22] We
examined the relationship between pre-eclampsia, gesta-
tional diabetes, and telomere length in a nested case-con-
trol study.
Methods
50 cases of pre-eclampsia, 25 cases of GDM, and 50 con-
t r o l s  w e r e  s e l e c t e d  f r o m  a n  e x i s t i n g  s t u d y ,  c o n d u c t e d
from April 1998 to June 2002 in Washington State. This
study has been described in detail elsewhere [33]. Using
the then-current guidelines, preeclampsia was defined as
sustained pregnancy-induced hypertension with protei-
nuria. Hypertension was defined as sustained blood pres-
sure readings of ≥ 140/90 mmHg (with readings taking
place ≥ 6 hours apart) and/or a sustained 15 mm Hg dia-
stolic rise or a 30 mm Hg systolic blood pressure above
first-trimester values. Proteinuria was defined as urine
protein concentrations of ≥ 30 mg/dl on ≥ 2 random
specimens collected at least 4 hours apart. In our study
setting, according to the recommendations from the
Table 1: Distribution of Preeclampsia (PE) Cases and Normotensive Control Subjects According to Selected Characteristics, 
Seattle and Tacoma, Washington, 1998 - 2002.
PE Cases Control Subjects p
(N = 50) (N = 50)
n%n%
Maternal Age (years) <0.01
2 0 - 2 4 1 9 3 851 0
25-29 13 26 14 28
30-34 18 36 31 62
Maternal Age (years)† 27.3 ± 0.6 29.5 ± 0.5 <0.01
Maternal Race/Ethnicity
Non-Hispanic White 50 100 50 100 ..
U n m a r r i e d 1 3 2 681 6 0 . 2 2
≤ 12 years Education 15 30 3 6 <0.01
Nulliparous 50 100 50 100 ...
Smoked During Pregnancy 11 22 7 14.8 0.06
Pre-pregnancy BMI*† 26.9 ± 0.9 22.4 ± 0.4 <0.01
Pre-pregnancy BMI* <0.01
< 20 1 2 13 26
20-24.9 25 50 27 54
25-29.9 11 22 8 16
≥ 30 13 26 2 4
Annual Household Income (US$) 0.36
<30,000 9 18 9 18
30,000-69,999 24 48 17 34
70,000+ 17 34 23 46
U n k n o w n 0012
Physical inactive during pregnancy 24 48 16 32 0.10
Family history of chronic hypertension 29 58 17 34 0.02
Gestational age at delivery (weeks) 34.4 ± 0.6 39.7 ± 0.2 <0.01
Time from last meal to blood drawn (hours) 3.03 ± 0.53 1.68 ± 0.19 0.02
Telomere length† 0.77 ± 0.02 0.77 ± 0.02 0.75
Median (inter-quartile range) 0.75 (0.66, 0.83) 0.77 (0.70, 0.84) 0.56
*Pre-pregnancy body mass index = BMI = weight (kg)/height (m2).
†Mean ± SEM;Harville et al. BMC Research Notes 2010, 3:113
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American Diabetes Association (ADA) [34] pregnant
women were screened at 24-28 weeks gestation using a 50
gram 1-hour oral glucose challenge test. Those patients
who failed this screening test (glucose ≥ 7.8 mmol/L)
were then followed-up within 1-2 weeks with a 100 g, 3-h
oral glucose tolerance test (OGTT). We also abstracted
laboratory results from participants' 50 gram 1-hour glu-
cose challenge test and from the diagnostic 100 gram 3-
hour OGTT. Women were diagnosed with GDM if two or
more of the 100 gram OGTT glucose levels exceeded the
ADA criteria [34]: fasting >5.3 mmol/L; 1-hour >10.0
mmol/L; 2-hour >8.6 mmol/L; 3-hour >7.8 mmol/L.
Controls were women who delivered within two hours
of a case with pregnancies uncomplicated by pregnancy-
induced hypertension. A structured interview question-
naire, administered during participants' postpartum hos-
pital stay, was used to collect information on maternal
sociodemographic, medical, reproductive, and lifestyle
Table 2: Distribution of Gestational Diabetes Mellitus (GDM) Cases and Normotensive/Euglycemic Control Subjects 
According to Selected Characteristics, Seattle and Tacoma, Washington, 1998 - 2002.
GDM Cases Control Subjects p
(N = 25) (N = 50)
n%n%
Maternal Age (years) 0.29
20-24 3 12 5 10
25-29 3 12 14 28
3 0 - 3 4 1 97 63 16 2
Maternal Age (years)† 30.9 ± 0.7 29.5 ± 0.5 0.08
Maternal Race/Ethnicity
Non-Hispanic White 25 100 50 100 ---
U n m a r r i e d 31 281 6 0 . 7 4
≤ 12 years Education 1 4 3 6 0.59
N u l l i p a r o u s 1 24 85 0 1 0 0 < 0 . 0 1
Smoked During Pregnancy 2 8 7 14.8 0.54
Pre-pregnancy BMI*† 27.8 ± 1.5 22.4 ± 0.4 <0.01
Pre-pregnancy BMI* <0.01
<  2 0 3 1 21 32 6
20-24.9 7 28 27 54
25-29.9 7 28 8 16
≥  3 0 83 22 4
Annual Household Income (US$)
<30,000 5 20 9 18 0.93
30,000-69,999 7 28 17 34
7 0 , 0 0 0 + 1 24 82 34 6
U n k n o w n 1412
Physical inactive during 
pregnancy
10 40 16 32 0.49
Family history of diabetes mellitus 4 16 3 6 0.21
Gestational age at delivery (weeks) 39.0 ± 0.2 39.7 ± 0.2 0.05
Time from last meal to blood 
drawn (hours)
3.25 ± 0.74 1.68 ± 0.19 <0.01
Telomere length† 0.73 ± 0.02 0.77 ± 0.02 0.20
Median (inter-quartile range) 0.72 (0.69, 0.76) 0.77 (0.70, 0.84) 0.10
*Pre-pregnancy body mass index = BMI = weight (kg)/height (m2).
†Mean ± SEM;Harville et al. BMC Research Notes 2010, 3:113
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characteristics during in-person interviews. The women
chosen for this analysis were required to be between 20-
35 years old, non-Hispanic white, with no pre-existing
hypertension or diabetes, and carrying a singleton preg-
nancy.
Non-fasting blood samples were collected in 10 ml tri-
potassium EDTA Vacutainer tubes during the intrapar-
tum period. These were protected from ultraviolet light,
kept on wet ice, and processed within 30 minutes of phle-
botomy. Plasma was decanted into cryovials and kept fro-
zen at -70°C or below until analysis.
Leucocyte telomere length (hereafter referred to as
telomere length) was measured by Quantitative-PCR
using the method described by Cawthon [35]. Briefly, for
each sample, two PCRs are performed: the first one to
amplify the telomeric DNA and the second one to
amplify a single-copy control gene (36B4, acidic ribo-
somal phosphoprotein PO). This provides an internal
control to normalize the starting amount of DNA. The
amount of telomeric DNA is divided by the amount of
control-gene DNA, producing a relative measurement of
the telomere length of the sample. The average inter-
experimental coefficient of variation was 0.05.
Sample size for this study was determined based on
other studies of telomere length. Comparing groups of 50
gives us better than 90% power to see a difference as large
as that seen in a paper demonstrating reduced telomere
length under chronically stressful conditions [36]. Fifty
per group gives us 80% power to see an odds ratio of 3.2
for top vs. bottom quartile, lower than the hazard ratio of
3.5 seen in previous studies of telomere length and cancer
[37]. Several studies of this size looking at telomere
length and reproductive outcomes have been pub-
lished[22,30,32]
Mean and median telomere length among cases and
controls was compared using t-tests and Wilcoxon non-
parametric tests. Telomere length was divided into tertile
based on the control group, and logistic regression was
used to model the outcomes as a function of tertile telom-
ere length, with control for effects of potential confound-
ers. In addition, the association between telomere length
and other variables was examined within cases and con-
trols.
Ethics approval for the initial study was granted by the
University of Washington Institutional Review Board,
and informed consent (including for sample banking) was
gathered from all subjects. Tulane University IRB granted
approval for this secondary analysis.
Results
Pre-eclampsia cases were on average younger, heavier,
more likely to smoke, less likely to have higher education,
and more likely to have a family history of hypertension
than controls (table 1). GDM cases were on average older,
heavier, and more likely to have a family history of diabe-
tes (table 2). Mean telomere length in pre-eclampsia cases
Table 3: Odds Ratios (OR) and 95% Confidence Intervals (CI) for Preeclampsia (PE) and gestational diabetes mellitus (GDM) 
according to Tertiles of Maternal Blood DNA Telomere Length Sampled at Delivery, Seattle, Washington, 1998-2002.
Telomere length Preeclampsia (N = 50) Controls Unadjusted OR Age-adjusted OR Adjusted OR*
(N = 50) (95%CI) (95%CI) (95%CI)
Tertile 1 (<0.720) 23 19 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (0.720-0.800) 8 15 0.44 (0.15-1.26) 0.45 (0.15-1.35) 0.46 (0.62-3.38)
Tertile 3 (≥ 0.801) 19 16 0.98 (0.40-2.41) 1.08 (0.42-2.75) 0.92 (0.15-5.46)
P for trend 0.91 0.94 0.83
Telomere length GDM Controls Unadjusted OR Age-Adjusted OR Adjusted OR*
(N = 25) (N = 50) (95%CI) (95%CI) (95%CI)
Tertile 1 (<0.720) 14 19 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (0.720-0.800) 6 15 0.54 (0.17-1.75) 0.56 (0.17-1.87) 0.96 (0.19-4.77)
Tertile 3 (≥ 0.801) 5 16 0.42 (0.13-1.43) 0.35 (0.10-1.23) 0.65 (0.13-3.34)
P for trend 0.15 0.09 0.61
The cutoffs of tertile were based on the distribution in controls
* adjusted for maternal age, pre-pregnancy body mass index, gestational age at delivery and time from last meal to blood draw.Harville et al. BMC Research Notes 2010, 3:113
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was 0.77 (SD 0.14), in GDM cases was 0.73 (SD 0.10), and
in controls was 0.77 (SD 0.14). If the pre-eclampsia cases
were limited to those who gave birth preterm (n = 30),
mean telomere length was 0.79 (SD 0.15), which was not
significantly different from that of controls. Odds of pre-
eclampsia were lowest in the middle tertile of telomere
length and essentially equal in the lowest and highest ter-
tiles in the unadjusted and both adjusted models (table 3).
There was evidence of reduced risk of GDM with the
highest tertile of telomere length, though the associations
did not reach statistical significance in any of the 3 mod-
els tested.
Among controls, covariates were examined for rela-
tionships with telomere length. There was some evidence
of association with telomere length for hours since last
meal (r = 0.24, p = 0.09) and birthweight (r = 0.24, p =
0.10). Among the controls, mean telomere length was
shorter in preterm infants (0.69 vs. 0.78, p = 0.26), ever
smokers (0.74 and 0.79, p = 0.25), unmarried women
(0.72 vs. 0.78, p = 0.18), and those who had eaten most
recently (0.73 vs. 0.82, p = 0.05).
Discussion
The main findings of the study are (1) no association of
telomere length with pre-eclampsia, and (2) shorter
telomeres associated with gestational diabetes, but differ-
ences might be due to chance. The findings for pre-
eclampsia are in contrast with previous studies that have
reported shorter telomeres in individuals with hyperten-
sion and blood pressure [6-9,11-13], as well as a study
finding shorter telomeres in the placentas of pre-eclamp-
tic women[29] It may be that telomere attrition in hyper-
tension may take years to accumulate, at least in
leucocytes, and thus is not apparent in acute pre-eclamp-
tic hypertension. However, some prior studies that
explored the association of telomere length with cardio-
vascular diseases also failed to find an association with
hypertension, [11,38] suggesting that this association may
depend on the characteristics of the study population.
We found a trend of shorter telomeres in women with
gestational diabetes. This is in agreement with previous
studies that have reported shorter telomeres in individu-
als with type 2 diabetes mellitus[11,14,16,19] The lack of
statistical significance in our study is likely to be due to
the small number of cases, as leukocyte telomere length is
highly variable between individuals, or the trend we see
could simply be due to chance variation. In addition, as
with pre-eclampsia, variations in the pregnancy-related
and chronic form of this disease and the characteristics of
the study population could also account for the lack of
significant association in this study.
The difference in mean telomere length for pre-
eclampsia was 0.008, with a standard deviation of approx-
imately 0.14. To have 80% power to see a difference that
large, more than 5000 samples would need to be tested.
To see an odds ratio of 0.92, approximately 8000 samples
would be required. The difference in mean telomere
length for GDM was 0.01, with a standard deviation of
approximately 0.14. To have 80% power to see a differ-
ence that large, more than 3000 samples would need to be
tested. To have 80% power to see an odds ratio of 0.65,
approximately 325 cases and controls would be required.
Thus, in both cases a much larger set of samples than that
included in this study would be needed. Moreover, future
studies should also address the analysis of additional
markers of oxidative stress as well as leukocyte telom-
erase activity, as these parameters might help elucidate
the biological and functional role of telomere shortening
in these diseases.
Conclusions
The odds ratio for GDM was lowest in the highest tertile
of telomere length, but the associations did not reach sta-
tistical significance. No association was seen with pre-
eclampsia. Further research is necessary to determine if
telomere length is associated with pregnancy complica-
tions or outcomes.
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